Prof. Dr. Dr. Thomas A. Wichelhaus
PD Dr. Dr. Silke Besier
Denia Frank (MTA)
The evolution of increasingly antimicrobial-resistant strains of S. aureus results from a multitude of factors that include the widespread and sometimes inappropriate use of antimicrobials, the extensive use of various agents as growth promoters in animal feed, and, with the increase in regional and international travel, the relative ease with which antimicrobial-resistant strains cross geographic barriers. Our research focuses on the molecular analyses of antibiotic resistance mechanisms and the biological cost of resistance from the perspective of S. aureus. Understanding the molecular mechanisms of resistance is one of the prerequisites for the identification of novel drug targets and finally for the development of effective new chemotherapeutic agents.
Colonization/infection with multidrug-resistant bacteria (MDRB) such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae, and carbapenemase producing Gram-negative pathogens is an increasing problem worldwide. Our research focuses on molecular mechanisms of resistance and epidemiology of MDRB.
Antimicrobial drug resistance in Neisseria gonorrhoeae has become an increasing public health problem. Hence, surveillance of resistance development is of crucial importance to implement adequate treatment guidelines. Our research focuses on the epidemiology of antibiotic resistance among gonococcal isolates in Germany.
The alarming increase of antibiotic-resistant bacterial pathogens points to the need for new antiinfective therapies. Consequently, antibiotic resistance has been called one of the world’s most pressing public health problems. A worrisome trend is the spread of metallo-β-lactamases among Gram-negative pathogens that can confer resistance to almost all β-lactams including carbapenems and consequently present a major challenge for treatment of individual patients.
Our research focuses on the development and evaluation of new antimicrobials active against MDRB. In particular our research aims at developing a new anti-infective agent by identifying metallo-β-lactamase inhibitors which will restore the bactericidal activity of common β-lactam antibiotics against multidrug-resistant Gram-negative pathogens.